Lopressor patient counseling information: Difference between revisions

Metoprolol
Clinical data
Trade names	Lopressor, Toprol-xl
AHFS/Drugs.com	Monograph
MedlinePlus	a682864
[[Regulation of therapeutic goods \|Template:Engvar data]]	US FDA: Metoprolol;
Pregnancy; category	AU: C ; US: C (Risk not ruled out) ; ;
Routes of; administration	Oral, IV
ATC code	C07AB02 (WHO) ;
Legal status
Legal status	In general: ℞ (Prescription only);
Pharmacokinetic data
Bioavailability	12%
Metabolism	Hepatic via CYP2D6, CYP3A4
Elimination half-life	3-7 hours
Excretion	Renal
Identifiers
	IUPAC name (RS)-1-(Isopropylamino)-3-[4-(2-methoxyethyl)phenoxy]propan-2-ol;
CAS Number	51384-51-1 ;
PubChem CID	4171;
IUPHAR/BPS	553;
DrugBank	DB00264 ;
ChemSpider	4027 ;
UNII	GEB06NHM23;
KEGG	D02358 ;
ChEBI	CHEBI:6904 ;
ChEMBL	ChEMBL13 ;
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C15H25NO3
Molar mass	267.364 g/mol
3D model (JSmol)	Interactive image;
Melting point	120 °C (248 °F)
	SMILES O(c1ccc(cc1)CCOC)CC(O)CNC(C)C;
	InChI InChI=1S/C15H25NO3/c1-12(2)16-10-14(17)11-19-15-6-4-13(5-7-15)8-9-18-3/h4-7,12,14,16-17H,8-11H2,1-3H3 ; Key:IUBSYMUCCVWXPE-UHFFFAOYSA-N ;
(verify)

Revision as of 17:48, 4 February 2014

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2]

Advise patients to :

Take Lopressor regularly and continuously, as directed, with or immediately following meals.
If a dose should be missed, the patient should take only the next scheduled dose (without doubling it). :*Patients should not discontinue Lopressor without consulting the physician.
Avoid operating automobiles and machinery or engaging in other tasks requiring alertness until the patient’s response to therapy with Lopressor has been determined.
Contact the physician if any difficulty in breathing occurs.
Inform the physician or dentist before any type of surgery that he or she is taking Lopressor.^[1]

Adapted from the FDA Package Insert.

@@ Line 3: / Line 3: @@
 {{CMG}}; {{AE}} {{AZ}}
+==Information for Patients==
+Advise patients to :
-<ref name="dailymed.nlm.nih.gov">{{Cite web  | last =  | first =  | title = LOPRESSOR (METOPROLOL TARTRATE) TABLET [NOVARTIS PHARMACEUTICALS CORPORATION] | url =http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=bb05420c-fd24-4672-9f62-fdd313819287 | publisher =  | date =  | accessdate = }}</ref>
+:*Take Lopressor regularly and continuously, as directed, with or immediately following meals.
+:*If a dose should be missed, the patient should take only the next scheduled dose (without doubling it). :*Patients should not discontinue Lopressor without consulting the physician.
+:*Avoid operating automobiles and machinery or engaging in other tasks requiring alertness until the patient’s response to therapy with Lopressor has been determined.
+:*Contact the physician if any difficulty in breathing occurs.
+:*Inform the physician or dentist before any type of surgery that he or she is taking Lopressor.<ref name="dailymed.nlm.nih.gov">{{Cite web  | last =  | first =  | title = LOPRESSOR (METOPROLOL TARTRATE) TABLET [NOVARTIS PHARMACEUTICALS CORPORATION] | url =http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=bb05420c-fd24-4672-9f62-fdd313819287 | publisher =  | date =  | accessdate = }}</ref>
 ==References==
 {{Reflist}}